CDK9 and cancer: CDK9 reactivates epigenetically silenced genes in cancer, and inhibition of CDK9 by drugs such as flavopiridol, dinaciclib, seliciclib, SNS-032, and RGB-286638 is exploited in cancer therapy (44, 45).